9.1 Toxicology and Antidote Therapy in the ICU

Toxicology and Antidote Therapy in the ICU

The management of the poisoned patient in the intensive care unit requires a systematic approach. While specific antidotes exist for a minority of toxins, excellent supportive care—managing the airway, breathing, and circulation (the ABCs)—remains the cornerstone of toxicologic resuscitation.

General Approach to the Poisoned Patient

Initial evaluation focuses on resuscitation and stabilization. Following stabilization, the clinician must focus on risk assessment, decontamination, enhanced elimination, and targeted antidote therapy.

Toxidromes

Recognizing a "toxidrome" (toxic syndrome) can help identify the offending agent when the history is unknown.

Specific Poisonings and Antidotes

Acetaminophen (APAP)

Acetaminophen toxicity is a leading cause of acute liver failure. In overdose, the sulfation and glucuronidation pathways are saturated, leading to increased metabolism via CYP2E1 to NAPQI, a toxic free radical. Depletion of glutathione prevents the neutralization of NAPQI, resulting in centrilobular hepatic necrosis.

Management:

• N-acetylcysteine (NAC): Restores hepatic glutathione stores and serves as a glutathione substitute. It is nearly 100% effective in preventing hepatotoxicity if started within 8 hours of ingestion.
• Rumack-Matthew Nomogram: Used for acute, single ingestions. A serum APAP level drawn between 4 and 24 hours post-ingestion is plotted on the nomogram. Levels above the treatment line warrant NAC therapy. It is not used for chronic ingestions or staggered overdoses.

Toxic Alcohols: Methanol and Ethylene Glycol

Both methanol and ethylene glycol cause an elevated anion gap metabolic acidosis and an elevated osmolar gap (though the osmolar gap closes as the parent alcohol is metabolized to toxic acids).

• Methanol: Metabolized to formic acid. Causes retinal toxicity ("snowstorm" vision) and basal ganglia putaminal necrosis.
• Ethylene Glycol: Metabolized to glycolic and oxalic acid. Causes acute kidney injury (calcium oxalate crystals in urine).

Management:

• Fomepizole (4-MP): A competitive inhibitor of alcohol dehydrogenase (ADH). By blocking ADH, it prevents the parent alcohol from being converted into its toxic metabolites.
• Hemodialysis: Indicated for severe metabolic acidosis, renal failure, visual disturbances (methanol), or very high serum levels. Fomepizole is dialyzable, so the dosing frequency must be increased during hemodialysis.
• Cofactors: Folic acid (for methanol) and thiamine/pyridoxine (for ethylene glycol) to drive metabolism toward non-toxic pathways.

Cardiovascular Toxins: Beta-Blockers and Calcium Channel Blockers

Overdoses of beta-blockers (BBs) and calcium channel blockers (CCBs) frequently present with severe bradycardia, hypotension, and cardiogenic shock.

Management Strategies:

• Atropine & Fluids: Often ineffective but used initially.
• Calcium: (Gluconate or Chloride) Used particularly for CCB overdose to overcome competitive blockade, though it rarely corrects hypotension fully.
• Glucagon: Historically a first-line agent, especially for BB toxicity. It stimulates adenylate cyclase independently of the beta-receptor, increasing intracellular cAMP. Efficacy is variable and it causes significant vomiting.
• High-Dose Insulin Euglycemia Therapy (HIET): A cornerstone of severe CCB/BB toxicity. The ischemic/stressed myocardium shifts from using free fatty acids to carbohydrates. HIET facilitates myocardial carbohydrate uptake, acting as a potent inotrope. Dosing typically starts at 1 Unit/kg bolus followed by 1-10 Units/kg/hr infusion, requiring aggressive dextrose (to prevent hypoglycemia) and potassium (to prevent hypokalemia) supplementation.
• Intravenous Lipid Emulsion (ILE): Acts as a "lipid sink" for highly lipophilic drugs (e.g., verapamil, propranolol, local anesthetics) and may also provide a direct myocardial energy source.

Tricyclic Antidepressants (TCAs)

TCA overdose can be fatal due to sodium channel blockade, leading to QRS widening and fatal ventricular dysrhythmias, as well as anticholinergic toxicity and alpha-1 blockade (hypotension).

Management:

• Sodium Bicarbonate: The primary treatment for TCA-induced cardiotoxicity. It works by increasing the serum pH (which increases the non-ionized fraction of the drug, decreasing sodium channel binding) and providing a large sodium load to overcome the competitive sodium channel blockade. It is indicated when the QRS complex is > 100 msec or for ventricular dysrhythmias.
• Avoid Physostigmine: Although TCAs cause anticholinergic toxicity, physostigmine can precipitate asystole in the setting of TCA overdose.

Salicylates (Aspirin)

Salicylates cause a mixed primary respiratory alkalosis (direct stimulation of the medullary respiratory center) and a primary elevated anion gap metabolic acidosis (uncoupling of oxidative phosphorylation).

Management:

• Urinary Alkalinization: Sodium bicarbonate infusion targets a urine pH of 7.5 to 8.0. Salicylic acid is a weak acid; alkalinizing the urine traps it in its ionized form within the renal tubules, preventing reabsorption and enhancing excretion (ion trapping). Hypokalemia must be corrected, as the kidneys will excrete H+ instead of K+ in the presence of hypokalemia, preventing urine alkalinization.
• Hemodialysis: The definitive treatment for severe toxicity (e.g., altered mental status, pulmonary edema, renal failure, or very high levels, typically > 100 mg/dL).